Страна: Велика Британія
мова: англійська
Джерело: VMD (Veterinary Medicines Directorate)
Feline leukemia virus
Boehringer Ingelheim Vetmedica Gmbh
QI06AD07
Feline leukemia virus
Suspension for injection
POM-V - Prescription Only Medicine – Veterinarian
Cats
Live Viral Vaccine
Authorized
2000-04-13
Issued: April 2022 AN: 02837/2021 Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Purevax FeLV suspension for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 1 ml or 0.5 ml contains: ACTIVE SUBSTANCE: FeLV recombinant Canarypox virus (vCP97)...............................≥ 10 7.2 CCID50 1 1 cell culture infective dose 50% EXCIPIENTS: For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Suspension for injection. Clear colourless liquid with presence of cell debris in suspension. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Cats. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Active immunisation of cats of 8 weeks of age or older against feline leukaemia for the prevention of persistent viraemia and clinical signs of the related disease. Onset of immunity: 2 weeks after primary vaccination course. Duration of immunity: 1 year after the last vaccination. 4.3 CONTRAINDICATIONS None. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Vaccinate healthy animals only. Issued: April 2022 AN: 02837/2021 Page 2 of 5 4.5 SPECIAL PRECAUTIONS FOR USE Special precautions for use in animals It is recommended that a test for FeLV antigenaemia be carried out prior to vaccination. Vaccination of FeLV positive cats is of no benefit. Special precautions to be taken by the person administering the veterinary medicinal product to animals In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. 4.6 ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS) A temporary small (< 2 cm) nodule, which regresses within 1 to 4 weeks, was very commonly observed at the site of injection during safety and field studies. Transient lethargy and hyperthermia were very commonly observed during safety and field studies and lasted usually for 1 day, exceptionally for 2 days. Anorexia and emesis have been reported very rarely based on post marketing safety experience. A hypersensitivity reaction may occur in ver Прочитайте повний документ